Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Study of Radiotherapy and Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): The RaDD Study

NCT03610061 is registered in ClinicalTrials.gov with Austin Health as lead sponsor.

NCT NCT03610061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Study of Radiotherapy and Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): The RaDD Study
Lead sponsor
Austin Health
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2018
Completion date
April 8, 2024
Enrollment
34 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma